Fulltext

Prognostic Value of Viremia in Patients with Long-Standing Human Immunodeficiency Virus Infection

Galetto-Lacour, Annick ; Yerly, Sabine ; Perneger, Thomas V. ; Baumberger, Christophe ; Hirschel, Bernard ; Perrin, Luc

In: Journal of Infectious Diseases, 1996, vol. 173, no. 6, p. 1388-1393

Ajouter à la liste personnelle
    Titre
    • Prognostic Value of Viremia in Patients with Long-Standing Human Immunodeficiency Virus Infection
    Auteur
    • Galetto-Lacour, Annick. Division of Infectious Diseases, Central Laboratory of Virology, and AIDS Center, Institute of Social and Preventive Medicine, Geneva University Hospital, Geneva, Switzerland
    • Yerly, Sabine. Division of Infectious Diseases, Central Laboratory of Virology, and AIDS Center, Institute of Social and Preventive Medicine, Geneva University Hospital, Geneva, Switzerland
    • Perneger, Thomas V.. Division of Infectious Diseases, Central Laboratory of Virology, and AIDS Center, Institute of Social and Preventive Medicine, Geneva University Hospital, Geneva, Switzerland
    • Baumberger, Christophe. Division of Infectious Diseases, Central Laboratory of Virology, and AIDS Center, Institute of Social and Preventive Medicine, Geneva University Hospital, Geneva, Switzerland
    • Hirschel, Bernard. Division of Infectious Diseases, Central Laboratory of Virology, and AIDS Center, Institute of Social and Preventive Medicine, Geneva University Hospital, Geneva, Switzerland
    • Perrin, Luc. Division of Infectious Diseases, Central Laboratory of Virology, and AIDS Center, Institute of Social and Preventive Medicine, Geneva University Hospital, Geneva, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Journal of Infectious Diseases, 1996, vol. 173, no. 6, p. 1388-1393. The University of Chicago Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:300169
    Summary
    Human immunodeficiency virus (HIV) viremia was evaluated in 73 patients with long-standing infection to investigate its relationship with clinical or biologic parameters and to assess its use as a predictor of clinical progression and death. After adjustment for other parameters, baseline HIV RNA level was significantly associated with baseline clinical stage and CD4 cell count. During follow-up (mean, 14.6 months), 16 patients died; 34 others had clinical progression of disease. In multivariate analysis, mortality was better predicted by baseline CD4 cell count (relative hazard [RH] for 100-cell decrease, 3.5; 95% confidence interval [CI], 1.5-8.2; P = .003) than by HIV RNA (P = .28) or clinical stage. HIV RNA level was the best predictor of clinical progression (RH for 1 log increase, 2.8; 95% CI, 1.6-4.9; P < .001). Monitoring of HIV RNA level may help to identify patients who might benefit from antiretroviral or prophylactic therapy